Facebook Inc. (FB) Secures an IPO Court Win

Facebook Inc. (NASDAQ:FB) and NASDAQ have been uneasy allies in a courtroom in New York, as the two entities have been working through more than a dozen lawsuits that devolved from the botched IPO last May. The same federal judge is handling all of the cases, and he has made a couple of initial rulings to start the process of working through the maze of lawsuits.

Facebook Inc. (NASDAQ:FB) was able to win a victory against a group of shareholders, who claimed that Facebook executives like CEO Mark Zuckerberg and others failed to disclose some key information about the company at the time of the IPO, which affected these investors’ positions. The claim was that these executives did not inform everyone about the company’s risks in mobile advertising. However, Judge Robert Sweet dismissed the case by the investors, saying that the three investors bought their shares on the day of the IPO, which was sufficiently after Facebook had submitted several amendments to its IPO filing, and the company’s uncertainty about mobile monetization was mentioned in those amendments.

Facebook Inc (NASDAQ:FB)The investors – listed as William Cole, Hal Hubuschman and Linda Levy – also claimed that media reports released suggested that Facebook Inc. (NASDAQ:FB) had given certain information to analysts and a hand-picked group of investors. But Judge Sweet rejected that notion as well, saying that while the information might have been pertinent to the IPO, the plaintiffs could not prove that the information  “significantly altered the total mix of information in the marketplace.”

What do you think? Should Facebook Inc. (NASDAQ:FB) avoid accountability for what happened with the IPO, or how do you think Facebook was involved in its own problems with its offering? We’d like your thoughts in the comments section below.

DISCLOSURE: I own no positions in any stock mentioned.

Please see these related FB articles:

Facebook Among Those Winning the Future

Will Atlas Be Shrugged in Advertising?

Is Facebook Losing Its Cool?

Biotech Insider Alert - $5 Stock To Hit $40

$200 Million Dollar Healthcare Hedge Fund's #1 Best Idea Right Now

The best healthcare hedge fund out there right now is one of the largest shareholders in this biotech stock. The fund returned more than 20% in each of the last 2 years with a virtually fully hedged portfolio, and it's sending out a BUY signal on this biotech stock. Get your FREE REPORT today (retail value of $300)

This is a FREE report from Insider Monkey. Credit Card is NOT required.
X

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 129% in 2.5 years!! Wondering How?

Download a complete edition of our newsletter for free!